A New Obesity Pill Enters the Arena With Double-Digit Weight Loss

Structure-based drug developer Structure Therapeutics has reported that its experimental oral obesity therapy delivered up to 11% weight loss in a mid-stage clinical study, placing it among the most competitive non-injectable candidates in development. The pill demonstrated clinically meaningful reductions in body weight with a favorable tolerability profile, positioning it as a future challenger to injectable GLP-1 therapies. Market analysts note that oral formulations could dramatically expand patient adherence and long-term persistence, potentially transforming the commercial dynamics of obesity treatment. The results reinforce investor belief that the next wave of metabolic innovation will be pill-based, not needle-based.